Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus as Adjuvant Therapy in Locally Advanced Head and Neck Cancer
NCT01111058Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Apr 2010
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Everolimus with Placebo (2 arms). Primary endpoint: Progression Free Survival Rate at 2 years. Started Apr 2010; status: terminated.
02
Drugs
everolimus
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01111058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111058.